Company: NRX Pharmaceuticals, Inc.
Form Type: 8-K
Filing Date: 2024-08-14
Corporate Action: Spin-off
Type: Update
Accession Number: 000143774924026888
Comments: The document outlines a Securities Purchase Agreement entered into by NRx Pharmaceuticals, Inc. It details a financing transaction involving the sale of convertible promissory notes and warrants. There is no indication that this transaction qualifies as a spin-off.
Document Link: View Document
Additional details:
Newco Cik: 096ab3ea3d
Parent Cik: 1719406
File Number: 001-38302
Access 12: 000143774924
: 0
Spin Off Id: 720
Form Type: 8-K
Filing Date: 2024-08-12
Corporate Action: Spin-off
Type: Update
Accession Number: 000143774924026107
Comments: NRx Pharmaceuticals, Inc. announced a plan to undertake a partial spin-off of shares from its wholly-owned subsidiary, Hope Therapeutics, Inc., to its shareholders. The company anticipates that Hope will apply for listing on a national securities exchange following the spin-off. This strategic move aims to enhance the business portfolio, signaling growth potential. However, specifics about the spin-off date have not been disclosed in the announcement. This plan is an integral part of the company’s broader strategy for advancing its pharmaceutical development.
Document Link: View Document
Additional details:
Newco Cik: 096ab3ea3d
Parent Cik: 1719406
File Number: 001-38302
Access 12: 000143774924
: 0
Spin Off Id: 720
Form Type: 8-K
Filing Date: 2024-04-30
Corporate Action: Spin-off
Type: New
Accession Number: 000110465924055041
Comments: The document is primarily about a spin-off involving NRx Pharmaceuticals, indicating that on April 24, 2024, there was a notice related to the spin-off and its implications.
Document Link: View Document
Additional details:
Newco Cik: 096ab3ea3d
Parent Cik: 1719406
File Number: 001-38302
: